Ch 12: LAW RELATING TO PATENTS — Comprehensive ICSI Executive Test Series
CS Executive
📚 Economic, Commercial & Intellectual Property Laws
📖 Ch.12 — LAW RELATING TO PATENTS
⚖️ V3: Case Law & Landmark Precedents
⚡ Free Mode (Answers Locked)
⏱ Duration: 54 Mins
🎯 Total Marks: 30
Passed at: 12 Marks
Max Attempts: 10
⚖️ Statutory Applicability: Applicable for ICSI CS Executive Examinations (Latest Syllabus)
Answer ALL 3 questions. Deconstruct facts, cite controlling statutory provisions/precedents or show complete working notes for calculations.
📑 Exam Questions
3 Questions • Total 30 MarksQuestion 1: Patents Act 1970: Patentability criteria (Novelty, Inventive Step, Industrial Applicability)
10 Marks
📌 Latest ICSI Curriculum Standard for LAW RELATING TO PATENTS
Kalinga Bio-Pharma Ltd. filed a patent application for an improved compound derived from an existing anti-diabetic molecule, claiming enhanced bioavailability. The Patent Office objected, stating the invention lacks novelty and an inventive step under Section 2(1)(j) and Section 2(1)(ja) of the Patents Act, 1970, citing prior public disclosures and a published journal article by Dr. Ramesh Kumar. Kalinga Bio-Pharma argues that combining two known extracts creates a synergistic therapeutic effect not previously obvious to a person skilled in the art. Furthermore, the company asserts that the commercial viability and immense public demand establish industrial applicability. As the corporate legal counsel, critically evaluate the patentability of Kalinga Bio-Pharma's invention with specific reference to statutory criteria and judicial interpretations regarding inventive step and novelty.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 2: Inventions not patentable under Section 3: Section 3(d) efficacy test and Section 3(k) computer programme per se
10 Marks
📌 Latest ICSI Curriculum Standard for LAW RELATING TO PATENTS under the Patents Act, 1970
Kalyani Life Sciences Ltd. filed a patent application for a new crystalline polymorph of an existing cardiovascular drug, claiming enhanced bioavailability. Simultaneously, its subsidiary, TechVeda Software Solutions Pvt. Ltd., filed a patent for an artificial intelligence-driven algorithm embedded in a server that optimizes automated algorithmic trading without human intervention. The Controller of Patents objected to both applications under Section 3 of the Patents Act, 1970. Advise Kalyani Life Sciences Ltd. and TechVeda Software Solutions Pvt. Ltd. on the maintainability of their patent applications, citing relevant statutory provisions and landmark judicial precedents.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 3: Compulsory Licensing under Section 84: Grounds, 3-year timeline, and patent infringement remedies
10 Marks
📌 Latest ICSI Curriculum Standard for LAW RELATING TO PATENTS
M/s Zeneca Bio-Pharma Ltd., an Indian generic manufacturer, filed an application before the Controller of Patents for the grant of a compulsory licence under Section 84 of the Patents Act, 1970, in respect of Patent No. 543210 held by M/s Astra Remedies Corp. for a life-saving oncology drug. The patent was granted 4 years ago. Zeneca alleged that the reasonable requirements of the public have not been satisfied, the patented invention is not available to the public at an affordable price, and it is not worked in the territory of India. Meanwhile, Astra Remedies Corp. instituted an infringement suit against Zeneca before the High Court for unauthorized pre-grant reverse engineering. Examine the maintainability of the compulsory licence application and the sustainability of the infringement suit under the Patents Act, 1970, citing statutory provisions and judicial precedents.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Advertisement